CVRx to Report First Quarter 2023 Financial and Operating Results and Host Conference Call on April 27th, 2023GlobeNewsWire • 04/20/23
Totality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart FailureGlobeNewsWire • 03/21/23
CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference CallGlobeNewsWire • 03/16/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRXPRNewsWire • 03/13/23
Bronstein, Gewirtz & Grossman, LLC Notifies CVRx, Inc. (CVRX) Investors of InvestigationBusiness Wire • 02/23/23
CVRx stock tumbles after trial for heart failure therapy failed to meet primary endpoingMarket Watch • 02/21/23
CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical TrialGlobeNewsWire • 02/21/23
CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsGlobeNewsWire • 01/26/23
CVRx to Report Fourth Quarter and Fiscal Year 2022 Financial and Operating Results and Host Conference Call on January 26, 2023GlobeNewsWire • 01/12/23
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial ResultsGlobeNewsWire • 01/09/23
CVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022GlobeNewsWire • 10/18/22
CVRx, Inc. (CVRX) CEO Nadim Yared on Q2 2022 Results - Earnings Call TranscriptsSeeking Alpha • 07/29/22